Loading...
Loading...
ARIAD
Pharmaceuticals, Inc.
ARIA today announced results of its
review of updated clinical data from the pivotal PACE trial of Iclusig®
(ponatinib) and actions that it is taking following consultations with
the U.S. Food and Drug Administration (FDA).
With a median follow up of 24 months, serious arterial thrombosis
occurred in 11.8% of Iclusig-treated patients: cardiovascular events
6.2%, cerebrovascular events 4.0% and peripheral vascular events 3.6%
(some patients had more than one type of event). This compares to 8.0%
after 11 months of follow up reflected in the current U.S. prescribing
information.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in